Myriad Genetics, Inc. MYGN

Full chart Compare
Set alert

Price alert · MYGN

All alert types
5.94 USD -0.11 (-1.74%)

Nov 4, 2026, 2:02 PM EST

5.92 Day range 6.20
2.74 52-week range 8.09
YTD
-3.50%
1 year
-8.13%
Market cap
567.20M
Revenue (ttm)
837.60M
Profit margin
-15.20%
EPS (ttm)
-1.18
Shares out
91.30M
Forward P/E
71.53
YTD return
-3.50%
1-year return
-8.13%
Volume
779.46K
Avg volume
2.30M
Open
6.09
Previous close
6.04
Day's range
5.92 – 6.20
52-week range
2.74 – 8.09
Beta
1.89
Analysts
Buy
Price target
19.41 (+227.1%)

2Y -11.88 (-66.63%)

51015Jan 25Jun 25Nov 25Apr 26Aug 265.95

Key statistics

Enterprise value
1.05B
PEG ratio
0.00
Price / sales
1.17
Price / book
1.40
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
7.10%
Free cash flow
11.76M
Total cash
102.40M
Total debt
140.30M
Return on equity
-17.15%
Short % of float
8.31%
50-day average
13.32
200-day average
21.11

Financials — quick view

All financials
MYGN Revenue — quarterly 190.70M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MYGN Net income — quarterly -43.20M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MYGN EPS — quarterly -0.46
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MYGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2025Dec 1, 20240.030.030.000.00%
Nov 7, 2024Sep 1, 20240.020.06+0.04+200.00%
Aug 6, 2024Jun 1, 2024—0.05+0.06+600.00%
Feb 27, 2024Dec 1, 20230.020.04+0.02+100.00%

Upgrades / downgrades

MYGN analyst upgrades and downgrades
DateFirmActionFromTo
Feb 25, 2025Raymond JamesreitOutperformOutperform
Feb 25, 2025UBSmainNeutralNeutral
Feb 12, 2025Craig-Halluminit—Buy
Jan 30, 2025Piper SandlermainNeutralNeutral
Jan 28, 2025Goldman SachsmainBuyBuy
Jan 16, 2025Stephens & Co.reitEqual-WeightEqual-Weight

About Myriad Genetics, Inc.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
myriad.com

News

Your note

Sign in to keep a note on MYGN — it syncs with the Stock Master app.

Insider holders

MYGN insider holders
InsiderRelationLatest transactionDateShares held
ANCONA MARGARETOfficerSaleAug 20, 202479,366
DAVIS MARK STEVENDirectorStock Award(Grant)Dec 9, 202422,816
DIAZ PAUL JChief Executive OfficerSaleOct 10, 2024962,378
DREISMANN HEINRICHDirectorSaleSep 8, 2024121,648
FOX JENNIFER LYNNEOfficerStock Award(Grant)Sep 2, 202461,771
KUMAR RASHMIDirectorSaleAug 18, 202477,392

Institution ownership

MYGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.17.47%15,907,593170.69MDec 30, 2024
Vanguard Group Inc11.63%10,591,043113.64MDec 30, 2024
Wellington Management Group, LLP6.60%6,004,59864.43MDec 30, 2024
State Street Corporation6.07%5,525,70559.29MDec 30, 2024
Millennium Management Llc4.77%4,345,19646.62MDec 30, 2024
Glenview Capital Management, Llc4.57%4,157,32444.61MDec 30, 2024

Fund ownership

MYGN fund ownership
Holder% heldSharesValueReported
iShares Core S&P Smallcap ETF6.47%5,889,36563.19MDec 30, 2024
Vanguard Explorer Fund, Inc.3.51%3,193,90234.27MOct 30, 2024
Vanguard Total Stock Market Index Fund2.97%2,701,05428.98MSep 29, 2024
iShares Russell 2000 ETF2.66%2,417,66125.94MDec 30, 2024
Vanguard Small-Cap Index Fund2.37%2,157,13823.15MSep 29, 2024
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF2.08%1,892,40920.31MDec 30, 2024